The DOI matches its Crossref record.
Circumvention of Anti-Adenovirus Neutralizing Immunity by Administration of an Adenoviral Vector of an Alternate Serotype
Abstract
Effective gene transfer and expression following repetitive administration of adenoviral (Ad) vectors in experimental animals is limited by anti-Ad neutralizing antibodies. Knowing that anti-Ad humoral immunity is serotype-specific, we hypothesized that anti-Ad neutralizing immunity could be circumvented using Ad vectors of different serotypes (Ad2, Ad5) within the same subgroup (C) to transfer and express beta-glucuronidase (beta glu) in the lung. Sprague-Dawley rats received an intratracheal administration of either Ad2 beta glu or Ad5 beta glu, and, 14 days later, repeat administration of either the same vector or a vector of a different serotype. Analysis of serum and bronchoalveolar lavage fluid following initial vector administration demonstrated systemic and local serotype-specific neutralizing antibodies. For both the Ad2 and Ad5 vectors, beta glu expression 24 hr following the second administration of the same serotype was < 30% of that of naive animals. In contrast, beta glu expression 24 hr following second administration of a different serotype Ad vector was similar to expression at 24 hr of naive animals receiving a single administration (Ad5 beta glu followed by Ad2 beta glu, as well as Ad2 beta glu followed by Ad5 beta glu; p > 0.2 both comparisons). Although the alternative serotype bypassed anti-Ad neutralizing immunity, persistence of expression was reduced compared to that following administration to naive animals. Compatible with this observation, systemic administration of the same vectors to C57B1/6 mice demonstrated induction of cytotoxic T lymphocytes directed against the beta glu transgene, as well as products of the Ad genome. Interestingly, intratracheal administration of vectors with different serotypes and different transgenes to rats resulted in longer expression (but still not normalized) compared to that achieved with vectors of different serotypes but the same transgene. These observations demonstrate that alternate use of Ad vectors from different serotypes within the same subgroup can circumvent anti-Ad humoral immunity to permit effective gene transfer after repeat administration, although the chronicity of expression is limited, likely by cellular immune process directed against both the transgene and viral gene products expressed by the vector.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
An overview of current delivery systems in cancer gene therapy
El-Aneed, A. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.09.013 · Cited by 693
Rosengart, T. K., Lee, L. Y., Patel, S. R., Sanborn, T. A., Parikh, M., Bergman, G. W., Hachamovitch, R., Szulc, M., Kligfield, P. D., Okin, P. M., et al. (1999) · Circulation · doi:10.1161/01.cir.100.5.468 · Cited by 656
Self-citationViral Vectors for Gene Therapy
Robbins, P. D., & Ghivizzani, S. C. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00020-5 · Cited by 529
Morral, N., O’Neal, W., Rice, K., Leland, M., Kaplan, J., Piedra, P. A., Zhou, H., Parks, R. J., Velji, R., Aguilar-Córdova, E., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12816 · Cited by 409
Barouch, D. H., Pau, M. G., Custers, J. H. H. V., Koudstaal, W., Kostense, S., Havenga, M. J. E., Truitt, D. M., Sumida, S. M., Kishko, M. G., Arthur, J. C., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6290 · Cited by 383
Song, W., Kong, H.-L., Carpenter, H., Torii, H., Granstein, R., Rafii, S., Moore, M. A. S., & Crystal, R. G. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1247 · Cited by 379
Self-citationAdenovirus: The First Effective In Vivo Gene Delivery Vector
Crystal, R. G. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.2527 · Cited by 341
Self-citationViral vectors for gene delivery to the nervous system
Davidson, B. L., & Breakefield, X. O. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1104 · Cited by 321
Rosenberg, S. A., Zhai, Y., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Seipp, C. A., Einhorn, J. H., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.24.1870-b · Cited by 312
Mack, C. A., Patel, S. R., Schwarz, E. A., Zanzonico, P., Hahn, R. T., Ilercil, A., Devereux, R. B., Goldsmith, S. J., Christian, T. F., Sanborn, T. A., et al. (1998) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(98)70455-6 · Cited by 305
Self-citationGutless adenovirus: last-generation adenovirus for gene therapy
Alba, R., Bosch, A., & Chillon, M. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302612 · Cited by 303
Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy
Jooss, K., & Chirmule, N. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302037 · Cited by 277
Nwanegbo, E., Vardas, E., Gao, W., Whittle, H., Sun, H., Rowe, D., Robbins, P. D., & Gambotto, A. (2004) · Clinical and Vaccine Immunology · doi:10.1128/cdli.11.2.351-357.2004 · Cited by 266
Adenoviral Vector Immunity: Its Implications and Circumvention Strategies
S. Ahi, Y., S. Bangari, D., & K. Mittal, S. (2011) · Current Gene Therapy · doi:10.2174/156652311796150372 · Cited by 185
De, B. P., Heguy, A., Hackett, N. R., Ferris, B., Leopold, P. L., Lee, J., Pierre, L., Gao, G., Wilson, J. M., & Crystal, R. G. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.003 · Cited by 129
“This is of particular interest in the case of a viral vector based on a virus to which there is extensive preexisting immunity in the human population, such as AAV2 and AAV5 [12–19,26].”
Self-citationCircumventing Antivector Immunity: Potential Use of Nonhuman Adenoviral Vectors
Lopez-Gordo, E., Podgorski, I. I., Downes, N., & Alemany, R. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.228 · Cited by 65
Genetic Modification of the Lung Directed Toward Treatment of Human Disease
Sondhi, D., Stiles, K. M., De, B. P., & Crystal, R. G. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.152 · Cited by 36
Self-citation
Metadata
- Authors
- Mack, C. A., Song, W.-R., Carpenter, H., Wickham, T. J., Kovesdi, I., Harvey, B.-G., Magovern, C. J., Isom, O. W., Rosengart, T., Falck-Pedersen, E., Hackett, N. R., Crystal, R. G., & Mastrangeli, A.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 1997-01
- Volume
- 8
- Issue
- 1
- Pages
- 99-109
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2062144971
- Cited by
- 192
- References
- 0
- FWCI
- 11.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.